A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells

Xiao-ning Gao1*, Ji Lin2*, Qiao-yang Ning1*, Li Gao1*, Yu-shi Yao1, Ji-hao Zhou1, Yong-hui Li1, Li-li Wang1, Li Yu1*

1 Department of Hematology, Chinese PLA General Hospital, Beijing, China, 2 Central Lab, Hainan Branch, Chinese PLA General Hospital, Sanya, China

Abstract

AML1-ETO fusion protein (AE) is generated by t(8;21)(q22;q22) chromosomal translocation, which is one of the most frequently observed structural abnormalities in acute myeloid leukemia (AML) and displays a pivotal role in leukemogenesis. The histone acetyltransferase p300 promotes self-renewal of leukemia cells by acetylating AE and facilitating its downstream gene expression as a transcriptional coactivator, suggesting that p300 may be a potential therapeutic target for AE-positive AML. However, the effects of p300 inhibitors on leukemia cells and the underlying mechanisms have not been extensively investigated. In the current study, we analyzed the anti-leukemia effects of C646, a selective and competitive p300 inhibitor, on AML cells. Results showed that C646 inhibited cellular proliferation, reduced colony formation, evoked partial cell cycle arrest in G1 phase, and induced apoptosis in AE-positive AML cell lines and primary blasts isolated from leukemic mice and AML patients. Nevertheless, no significant inhibitory effects were observed in granulocyte colony-stimulating factor-mobilized normal peripheral blood stem cells. Notably, AE-positive AML cells were more sensitive to lower C646 doses than AE-negative ones. And C646-induced growth inhibition on AE-positive AML cells was associated with reduced global histone H3 acetylation and declined c-kit and bcl-2 levels. Therefore, C646 may be a potential candidate for treating AE-positive AML.

Introduction

Leukemogenesis involves a variety of recurrent chromosomal abnormalities. t(8;21)(q22;q22) translocation is the most common chromosomal aberration identified in AML, which occurs in 40% of patients with French-American-British (FAB) M2 subtype and constitutes 12% of all newly-diagnosed cases [1]. This chromosomal translocation results in expression of AML1-ETO fusion oncogene. This oncogene encodes a fusion protein (AE) consisting of the conserved runt homology from hematopoietic transcription factor AML1 and the majority of ETO repressor, respectively encoded on chromosome 21 and 8. AE can repress gene expression via recruitment of co-repressors (e.g. NCoR and SMRT) and histone deacetylases by the ETO moiety [2–4], and it is also capable to activate gene expression [5]. Recently, it has been reported that AE binds the transcriptional coactivator p300 through its NHR1 domain, allowing AE and p300 to colocalize at the regulatory regions of various genes up-regulated by AE and involved in self-renewal of hematopoietic stem/progenitor cells (e.g. Id1, p21 and Egr1) [5]. The interaction between AE and p300 constitutes a key step for promoting self-renewal gene expression in leukemia cells and inhibition of p300 impairs its ability to promote leukemic transformation [5]. Therefore, p300 may be a potential therapeutic target for AE-positive leukemia.

p300 protein is a transcriptional co-activator with intrinsic histone acetyltransferase (HAT) activity, and it plays a crucial role in cell cycle progression, differentiation and apoptosis [6–9]. There is a distinct association between abnormal p300 activity and malignancies. Inhibition of p300 suppresses cellular growth in melanoma cells [10] and induces apoptosis in prostate cancer cells [11]. p300 activity is also required for G1/S transition in cancer cells [12–13]. Nevertheless, the fusion of the monocytic leukemia zinc finger protein gene to p300 gene has been identified in acute myeloid leukemia (AML) with t(8;22)(p11;q13) translocation, which is involved in leukemogenesis through aberrant histone acetylation [14–15]. The above evidence indicates the functional role of p300 as a tumor promoter and p300 inhibition may serve as a prospective approach for anti-tumor therapy.

Despite that anti-tumor activity of p300 inhibitors in other cancers has been reported [11,16], its effects on leukemia cells and the underlying mechanisms have not been extensively investigated. C646, identified by using a structure-based in silico screening, is a competitive p300 inhibitor and more selective than other
acetyltransferase [16]. C646 slows cell growth and impedes intracellular histone acetylation in several melanoma and lung cancer cell lines [16], prompting us to hypothesize that C646 might be a potential candidate for inhibiting cellular proliferation in AE-positive AML cells. Thus, we explored the effects of C646 on several AML cell lines, and primary blasts from a transgenic leukemia mouse model and initially-diagnosed AML patients. We found that C646 inhibited cellular proliferation, reduced colony formation, evoked partial cell cycle arrest in G1 phase, and induced apoptosis in AE-positive AML cells, while no significant inhibitory effects were observed in normal peripheral blood stem cells (PBSCs). Notably, the AE-positive AML cells were more sensitive to lower C646 doses than AE-negative ones. Moreover, C646-induced growth inhibition of AE-positive AML cells was associated with reduced histone H3 acetylation and declined c-kit and bcl-2 levels. These results suggest a remarkable potential of C646 for treating AE-positive AML.

Materials and Methods

Animals and transplantation of leukemia cells

Female C57BL/6 mice (age 42.0 ± 1.0 days, weight 16 ± 0.2 g) were supplied by the experimental animal center of our hospital. A total of 1 x 10^6 viable cryopreserved primary leukemia cells from AML1-ETO9a (AE9a) transgenic leukemia mice [17] (gifted by Shanghai Institute of Hematology, Shanghai, China) were injected into the tail vein of a C57BL/6 mouse. When the mouse became moribund, the spleen was separated under anesthesia for isolating fresh leukemia cells. After treated with C646 (Calbiochem, Darmstadt, Germany) or 0.1% DMSO for 24 h, the leukemia cells were harvested and subjected to colony formation assay by using Methocult H4230 (STEMCELL Technologies Inc., Vancouver, Canada). For cell cycle assay, the cells were washed twice with ice cold PBS and fixed in 70% ethanol at 4°C overnight, followed by incubation with 10 μg/mL Ribonuclease A (Sigma-Aldrich, St Louis, MO) at 37°C for 30 min. The cells were then incubated with 50 μg/mL propidium iodide (BD Biosciences Pharmingen, San Diego, USA). Flow cytometry analysis of DNA content was performed on a FACS calibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). ModFit LT software (Version 3.1, Verity Software House Inc., Topsham, ME, USA) was used for subsequent analysis. For apoptosis assay, cells were stained with Annexin V-FITC (BD Biosciences Pharmingen, San Diego, USA) or Annexin V-Alexa Fluor 647 (Life Technologies, Grand Island, USA), and analyzed by flow cytometer. FlowJo software (Version 7.6.1, Treestar, Ashland, OR, USA) was used for subsequent analysis.

Colonies formation assay

Cells were treated with C646 or DMSO as described above. After 24 h, cells were harvested and subjected to colony formation assay by using Methocult H4230 (STEMCELL Technologies Inc., Vancouver, Canada). For cell lines, they were plated in methylcellulose at a concentration of 1 x 10^5 cells/mL. For primary leukemia cells, 100 μg/L stem cell factor, 10 μg/L interleukin-3, 10 μg/L interleukin-6 and 10 μg/L granulocyte-macrophage colony-stimulating factor were added to the methylcellulose medium and the cells were seeded at a concentration of 1 x 10^3 cells/mL. Colony formation was assessed 7 to 14 d later. The frequency of colony forming units (CFU) was calculated as number of colonies counted/number of cells plated.

Western blot

Cells were treated with C646 or DMSO as described above. In some experiments, the pan-caspase inhibitor Q-VD-OPH (R&D Systems, Minneapolis, MN) was added at 50 μM 1 h prior to addition of C646. Total protein was extracted from cells using radio immunoprecipitation assay buffer (Sigma-Aldrich, St. Louis, USA) in the presence of protease inhibitor cocktail (Complete mini, Roche, Indianapolis, IN, USA). Polyacrylamide gel electrophoresis, tank-based transfer to Immobilon Hybond-C membranes (Amersham Biosciences) and immunodetection were performed with standard techniques. The following antibodies were used: caspase-9 (Asp330) antibody, cleaved caspase-8 (Asp391) (18C8) antibody, cleaved caspase-3 (Asp175) (5A1E) antibody (Cell Signaling Technology, Inc., Beverly, MA), AML1/RHD domain (Ab-2) antibody (Calbiochem, San Diego, CA), c-kit

serum. For SKNO-1 cells, 10 μg/L granulocyte-macrophage colony-stimulating factor (PeproTech, London, UK) was added to the medium. Primary AML blasts isolated from the spleen of transplanted AE9a leukemia mice or the bone marrow sample of AML patients, as well as normal PBSCs isolated from the healthy donor were cultured in Iscove’s Modified Dulbecco’s Medium (Invitrogen, Carlsbad, USA) supplemented with 20% fetal bovine serum, 100 μg/L stem cell factor, 10 μg/L interleukin-3, 10 μg/L interleukin-6 and 10 μg/L granulocyte-macrophage colony-stimulating factor (PeproTech, London, UK).
C646 Selectively Inhibits AE-Positive AML Cells

A

Kasumi-1

SKNO-1

Inhibition rate (%)

Time (hours)

0 24 48 72

0 24 48 72

- 10 μM C646
- 25 μM C646
- 60 μM C646

- 25 μM C446
- 50 μM C446

B

Kasumi-1

SKNO-1

Frequency of CFU (%)

DMSO
10 μM C646
25 μM C646
60 μM C646

DMSO
25 μM C646
50 μM C446

C

DMSO
2.5 μM C646
5.0 μM C646
7.5 μM C646
10 μM C646

Cell number

G1: 46.76%
G2: 7.98%
S: 45.26%

G1: 64.52%
G2: 10.03%
S: 25.45%

G1: 60.96%
G2: 14.95%
S: 24.09%

G1: 60.00%
G2: 7.72%
S: 31.26%

G1: 75.57%
G2: 1.78%
S: 22.65%

SKNO-1

Cell number

G1: 50.14%
G2: 1.91%
S: 48.35%

G1: 58.24%
G2: 2.86%
S: 40.91%

G1: 59.30%
G2: 3.70%
S: 37.00%

G1: 63.59%
G2: 2.91%
S: 33.49%

G1: 68.53%
G2: 1.87%
S: 29.60%

Propidium Iodide

Cell phase distribution (%)

Kasumi-1 C646 24 h

SKNO-1 C646 24 h

G1
S
G2

G1
S
G2

D

DMSO
10 μM C646
25 μM C646

C646 24 h

Kasumi-1

SKNO-1

Annexin V FITC

SSC

Apoptotic cells (%)

C646 10 μM

Apoptotic cells (%)

E

C646 (24 h)

C646 (10 μM)

C646 (25 μM)

Q-VD-OPh (50 μM)

Cleaved caspase-3

Cleaved caspase-8

Full length Caspase-9

Cleaved caspase-9

β-actin

- 19 kDa
- 43 kDa
- 41 kDa
- 43 kDa

- 37 kDa
- 35 kDa
- 35 kDa
- 43 kDa
(C-19) antibody (Santa Cruz Biotechnology, Santa Cruz, USA), bel-2 antibody (Bioworld Technology, St. Louis Park, USA), histone H3 antibody (Abcam plc., Cambridge, UK) and acetylated H3 antibody (Upstate Biotechnology, Buffalo, USA). β-actin antibody (Santa Cruz Biotechnology, Santa Cruz, USA) was used to normalize the amount of analyzed samples. Signals were visualized using Immobilon Western Chemiluminescent HRP substrate (Millipore Corporation, Billerica, MA) by exposure to films.

Quantitative real-time PCR

RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, USA) and cDNA was synthesized from 1 μg of total RNA using oligo(dT)15. Quantitative real-time PCR (qRT-PCR) was carried out in an ABI Prism 7500 Fast Real-time PCR System using TaqMan master mix (Applied Biosystems, Foster City, USA) according to the protocol. All data were normalized using the endogenous control (ABL). The sequences for the primers and probes were described in Table S1.

Statistical analysis

SPSS 15.0 software (SPSS Inc., Chicago, IL) was used to process the data. Student’s t test was applied to compare C646-induced changes to respective controls. The survival data were presented in a Kaplan-Meier format showing the percentage of mouse survival at various time-points post-transplantation. The overall survival comparisons among subtypes were performed by Mantel-Haenszel log-rank test. A P value of less than 0.05 was chosen as a threshold for statistical significance.

Results

C646 inhibited proliferation of Kasumi-1 and SKNO-1 cells through inducing cell cycle arrest and apoptosis

The AE-positive AML cell line Kasumi-1 has been proved more sensitive to C646 than the AE-negative AML cell line HL-60 and THP-1, as measured by growth inhibitory assay [5]. In the present study, we retested the growth inhibitory effects of C646 on Kasumi-1 and another AE-positive AML cell line SKNO-1, by using Cell Counting Kit-8 and methylcellulose colony formation assay. As shown in Figure 1A and 1B, both cellular growth and colony formation of Kasumi-1 and SKNO-1 cell lines were dramatically suppressed upon C646 treatment. We then investigated its effect on cell cycle via propidium iodide staining and flow cytometry. As shown in Figure 1C, C646 treatment for 24 h within the dose range from 2.5 to 10 μM induced a dose-dependent cell cycle arrest in G1 phase (upper panel). However, when C646 dose was higher than 10 μM or the incubation time was longer than 24 h, its effect on cell cycle arrest did not increase accordingly (Figure 1C, lower panel). Furthermore, C646 induced a dose-dependent upregulation in apoptosis determined by Annexin V-FITC staining and flow cytometry, with a minimum effective dose of 10 μM (Figure 1D). Although higher doses of C646 were required for inducing apoptosis than for inducing cell cycle arrest (10 ± 2.5 μM), the apoptotic percentage expressed a gradual increase over time. To further analyze the mechanism of C646-induced apoptosis, the dose- and time-course caspase cleavage were investigated by Western blot. C646 induced cleavage of caspases 3, 8, and 9 in Kasumi-1 cells. Increased cleavage occurred with increasing the concentration or exposure time of C646 (Figure 1E). To determine whether inhibition of caspases would reduce caspase cleavage induced by C646, Kasumi-1 cells were incubated with 50 μM pan-caspase inhibitor Q-VD-OPH and cDNA was synthesized from 1 μg of total RNA using oligo(dT)15. Quantitative real-time PCR (qRT-PCR) was carried out in an ABI Prism 7500 Fast Real-time PCR System using TaqMan master mix (Applied Biosystems, Foster City, USA) according to the protocol. All data were normalized using the endogenous control (ABL). The sequences for the primers and probes were described in Table S1.

C646 was more selective to AE-positive AML cells than AE-negative cells

We then tested whether C646 could induce cell cycle arrest or apoptosis in 4 AE-negative AML cell lines, HL-60, NB4, K562 and HEL. These cell lines treated with low dose of C646 (2.5 μM) showed only a marginal increase in the percentage of cells in G1 phase (Figure 2A). Even treated with 25 M C646, the apoptosis in HL-60, K562 and HEL cell lines could not be significantly triggered (Figure 2B). To further confirm the specificity of low dose of C646 for AE-positive cells, we evaluated its effects in an AE-inducible U937-92NE cell line. The U937-92NE cells grown in the presence of ZnSO4 with high expression of AE (Figure 3A), were more sensitive to the effects of C646 on cell cycle arrest and apoptosis than the cells grown in the absence of ZnSO4 and U937 wild type cells (Figure 3B and 3C). Together, these data suggested that C646 was more selective to AE-positive AML cell lines than AE-negative cells on inducing cell cycle arrest and apoptosis.

C646 also inhibited the growth of primary AE-positive AML blasts

To address whether C646 had similar effects on primary AML blasts, we first assessed the effects of C646 on AE9a transgenic mice blasts. This mouse model harbors leukemia cells expressing the AE9a splice variant, which includes an extra exon (exon 9a) of the ETO gene, encodes a C-terminally truncated AE protein and is expressed in the majority of t(8;21) patients [18]. The AE9a fusion gene was coexpressed with enhanced green fluorescent protein (EGFP) in retroviral Mgr1 vector. Therefore, we could monitor the leukemia blasts by detecting EGFP-positive cells via flow cytometry. As shown in Figure 4A and 4B, in vitro treatment of C646 induced a cell cycle arrest in G1 phase and a dramatic elevation in apoptotic percentage in the AML blasts isolated from the spleens of leukemia mice. The number and size of colonies formed in vitro were also markedly reduced upon C646 treatment (Figure 4C). Notably, the median survival time of recipient mice
Figure 2. Effects of C646 on cell cycle distribution and apoptosis in AE-negative AML cell lines. Four AE-negative AML cell lines were respectively treated with given doses of C646 or 0.1% DMSO for 24 h before being subjected to the cell cycle distribution (A) and apoptosis (B) assays, as described in Figure 1. Histograms showed means ± SD of 3 independent experiments. doi:10.1371/journal.pone.0055481.g002

Figure 3. Selectivity of C646 for AE-positive AML cell lines. (A) AE expression in U937, U937-AE cell lines. U937-AE cells were treated in the absence or the presence of 100 μM ZnSO4 for 16 h. The cells were lysed and western blotting performed with the indicated antibodies. Equalization of protein loading was verified on the same membrane by reprobing after stripping. Data shown were representative of 2 independent experiments. Cells treated as in (A) were incubated further with given doses of C646 or 0.1% DMSO for 24 h before being subjected to the cell cycle distribution (B) and apoptosis (C) assays, as described in Figure 1. Histograms showed means ± SD of 3 independent experiments. * P<0.05. doi:10.1371/journal.pone.0055481.g003
injected with C646-treated leukemia blasts were distinctly longer than those injected with DMSO-treated blasts (37 vs 30 d), indicating that C646 could suppress in vivo growth of transplanted leukemia blasts (Figure 4D).

Next, we assessed the effects of C646 on human primary leukemia blasts isolated from AE-positive and -negative AML patients and normal hematopoietic stem cells isolated from granulocyte colony-stimulating factor-mobilized PBSCs of 2 healthy donors. As shown in Figure 5A and 5B, C646 triggered marked cell cycle arrest and apoptosis in primary blasts from the AE-positive patients. The changes of cell cycle distribution and apoptosis observed in AE-negative sample and normal hematopoietic stem cells were considerably weaker compared with those in the AE-positive samples. Upon 10 μM of C646 treatment, a more significant reduction in colony formation was observed in AE-positive samples than that in AE-negative one, although the colony formation was strongly inhibited in both cases upon 25 μM of C646 treatment (Figure 5C). These results validated the high selectivity of C646 in the primary AE-positive AML blasts and its safety for normal hematopoietic stem cells.

C646 reduced the levels of acetylated histone H3, c-kit and bcl-2 in Kasumi-1 and SKNO-1 cells

To address the molecular mechanisms underlying C646-mediated cell cycle arrest and apoptosis, we detected the protein levels of acetylated H3 and total histone H3 in Kasumi-1 and SKNO-1 treated with and without C646. As expected, C646 treatment for 24 h induced significant reduction in global histone H3 acetylation in both cell lines (Figure 6A). Because c-kit proto-oncogene and bcl-2 anti-apoptotic gene appear to be abnormal activation and closely related to apoptosis, cell cycle and proliferation in AE-positive AML cells [19–21], we detected the effects of C646 on protein and mRNA levels of c-kit and bcl-2 by Western blot and qRT-PCR, respectively. Consistent with the induction of cell cycle arrest and apoptosis, a significant decrease of c-kit and bcl-2 protein levels were observed in Kasumi-1 and

Figure 4. C646 inhibited in vivo proliferation of primary AML blasts isolated from AE9a leukemia mice. The AML blasts were isolated from the spleen of transplanted AE9a mice and cultured with 10 μM C646 or 0.1% DMSO for 24 h before being subjected to the cell cycle distribution (A), apoptosis (B) and colony formation (C) assays. Histograms showed means ± SD of 3 independent experiments. * P<0.05. (D) Primary AML blasts isolated from the spleen of transplanted AE9a leukemia mice were treated with C646 or DMSO and injected into the tail vein of C57BL/6J mice at a dose of 1 x 10^6 cells/mouse, respectively, and the survival time of each mouse were recorded. doi:10.1371/journal.pone.0055481.g004

C646 Selectively Inhibits AE-Positive AML Cells
Figure 5. Selectivity of C646 for primary AE-positive AML blasts. The AML blasts were respectively isolated from the bone marrow samples of 2 t(8;21)(q22;q22) AML patients and a normal karyotype AML patient. The normal hematopoietic stem cells were isolated from granulocyte colony-
SKNO-1 cells treated with 10 μM of C646 (Figure 6B). There was also a slight decrease in c-kit and bcl-2 mRNA levels in Kasumi-1 cells, as well as bcl-2 mRNA levels in SKNO-1 cells, and no distinct alteration in c-kit mRNA levels in SKNO-1 cells (Figure 6C). These results revealed that post-transcriptional modulation such as C646-mediated histone deacetylation might participate in the repression of c-kit and bcl-2 levels, which accounted for the growth-inhibitory activity of C646 in AE-positive AML cells.

Discussion

In general, t(8;21) AML patients are considered as a favorable risk group, for more than 80% of younger cases can reach a complete remission. However, 40–50% of patients relapse and the long-term disease-free survival rate is around 60% [22]. Therefore, novel approaches to decrease the relapse of these patients are needed. As recruitment of HATs and histone deacetylases (HDACs) by AE fusion protein is a key step in AE-driven leukemogenesis, controlling HATs and HDACs may provide new targets for this subtype of leukemia. p300 belongs to a family of transcriptional coactivators with HAT activity, and C646 is a newly discovered competitive p300 inhibitor. C646 inhibits the growth of both melanoma and non-small cell lung cancer cell lines at 10 μM dose, with similar or higher potency as other p300 inhibitors [16]. C646 also inhibits the growth of primary blasts from t(8;21)-positive AML patients and Kasumi-1 cells, but has little effect on normal hematopoietic stem/progenitor cells [5]. Consistent with these reports, we also proved that C646 inhibited the growth and colony formation in AML cell lines Kasumi-1 and SKNO-1, which suggests a broad spectrum of anti-proliferation activity of C646 against tumor cell lines.

In addition to growth arrest, p300 is required for orderly G1/S transition in human cancer cells and inhibition of p300 induces block of progression into the S-phase of cell cycle and apoptosis [16,23]. In our research, C646 succeeded in inducing cell cycle arrest in G1 phase and apoptosis specifically in AE-positive cells, while inappreciable effects were found in AE-negative cells. These data suggest the selectivity of C646 activity against AE-positive AML cells. The pan-caspase inhibitor Q-VD-OPH inhibited C646-induced cleavage of caspases 3, 8, and 9, confirming the caspase-dependent apoptotic process. This also suggests that both extrinsic and intrinsic pathways are triggered by C646, in keeping with recent findings which showed that the proapoptotic activity of C646 is determined via multiple apoptotic pathways [11]. In addition, it is noteworthy that neither cell cycle arrest nor apoptosis were observed in normal PBSCs on C646 treatment, which presents a valuable evidence for the drug safety of C646 in potential clinical uses. Although HDAC inhibitors have been applied in clinical trials both for solid and hematologic malignancies, there are limited reports about HAT inhibitors. Being a HAT

Figure 6. C646 reduced expression of acetylated histone H3, c-kit and bcl-2 in AE-positive AML cell lines. Western blot analysis of (A) acetylated H3, total histone H3, (B) c-kit and bcl-2 proteins in Kasumi-1 and SKNO-1 cells after 24 h treatment with C646 or DMSO. The cells were lysed and western blotting performed with the indicated antibodies. Equalization of protein loading was verified on the same membrane by reprobing after stripping. Data shown were representative of 2 independent experiments. (C) qRT-PCR analysis of c-kit and bcl-2 mRNA levels in the cells after 24 h treatment with C646 or DMSO. Histograms show relative mRNA levels normalized to control ABL gene; means ± SD of 3 independent experiments. * P<0.05.

doi:10.1371_journal.pone.0055481.g006
inhibitor, C646 was proved very sensitive to primary blasts isolated from AE3a transgenic leukemia mice or an AE-positive AML patients in our study. These data further prompt the feasibility for C646 in pre-clinical application.

The ability of p300 to acetylate cellular proteins is critical for their functions in cell growth control. The HAT activity endows p300 the capacity to influence chromatin activity by modulating histones and several non-histone proteins [24]. To explore the underlying mechanisms of the apparent sensitivity of AE-positive leukemia cells to C646, we evaluated post-treatment levels of histone acetylation and expressions of c-kit and bcl-2 in Kasumi-1 and SKNO-1 cell lines, which characterized by harboring c-kit mutation/overexpression, as well as bcl-2 overexpression. Corresponding to the growth-inhibitory effects of C646 on AE-positive leukemia cells, there was a dose-dependent reduction in global histone H3 acetylation. It has been confirmed that aberrant activation of c-kit promotes cell cycle progression and contributes to abnormal cell proliferation by altering the tyrosine kinase signaling [19], and c-kit mutation cooperates with AE to induce leukemogenesis [20]. Moreover, acetylation of AE fusion protein by p300 participates in activating its targets [6], and AE can directly activate transcription of bcl-2 [21]. It is reasonable to speculate that p300 also participates in AE-mediated transcriptional activation of bcl-2, and down-regulation of c-kit and bcl-2 might involve in C646-mediated growth inhibition, cell cycle arrest and apoptosis in AE-positive AML cells. Therefore, the suppressive activity of C646 on aberrant expression of c-kit and bcl-2 explains the high selectivity and sensitivity of AE-positive cells to C646. Certainly, the effects of C646 on AE-positive AML cells reflect a collective suppression of histone acetylation, bcl-2, c-kit and other factors. Identification of these uncharted factors and their roles in AML cells remains the subject of future investigations.

In conclusion, C646 exerts anti-leukemia effects on AE-positive AML cells. C646 inhibits cellular proliferation, reduces colony formation, evokes partial cell cycle arrest in G1 phase, and induces apoptosis in AE-positive AML cells, with reduced histone H3 acetylation and declined c-kit and bcl-2 levels. The credible selectivity for AE-positive AML cells but not AE-negative ones, and the comparative safety for normal PBSCs provide C646 a nice perspective in the clinics. Further investigating the in vivo effects of C646 will undoubtedly promote its clinical application for relevant patients.

Supporting Information

Table S1 Sequences of the primers used in this study.

(DOC)

Acknowledgments

The authors are grateful to Dr. Shuijun Liu (University of Minnesota, MN) for his valuable assistance and support of the study.

Author Contributions

Conceived and designed the experiments: XNG JL. Performed the experiments: XNG QYN LG YSY JHZ YHL LLW. Analyzed the data: XNG JL. Wrote the paper: XNG JL LY.

References

1. Grisolano JL, O’Neal J, Cain J, Tomasson MH (2003) An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A 100: 9506–9511.
2. Elagib KE, Goldfarb AN (2007) Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett 251: 179–186.
3. Linggi B, Müller-Tidow C, van de Locht I, Hu M, Nip J, et al. (2002) The (8;21) fusion protein, AML1-ETO, specifically represses the transcription of the P14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8: 743–750.
4. Fazi F, Racanizzi S, Zardo G, Starne LM, Mancini M, et al. (2007) Epigenetic silencing of the myelopoesis regulator microRNA-223 by the AML1-ETO oncoprotein. Cancer Cell 12: 457–466.
5. Wang L, Gural A, Sun XJ, Zhao X, Perna F, et al. (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333: 765–769.
6. Giles RH, Peters DJ, Bunning MH (1990) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14: 170–183.
7. Giordano A, Avantaggiati ML (1999) p300 and CBP: partners for life and death. J Cell Physiol 181: 218–230.
8. Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 251: 179–186.
9. Chan HM, La Thangue NB (2001) p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114: 2363–2373.
10. Bowers EM, Yan G, Makhterje C, Ostry A, Wang L, et al. (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 17: 471–482.
11. Yang M, Kanbe E, Peterson LF, Royapati A, Xiao Y, et al. (2006) A previously unidentified alternatively spliced isoform of (8;21) transcript promotes leukemogenesis. Nat Med 12: 945–949.
12. Fazi F, Zardo G, Gelmetti V, Travaglini L, Cioddi A, et al. (2007) Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood 109: 4432–4450.
13. Feng LX, Ravindranath N, Dym M (2000) Stem cell factor/c-kit up-regulates cyclin D5 and promotes cell cycle progression via the phosphoinoside 3-kinase/ p70 S6 kinase pathway in spermatogonia. J Biol Chem 275: 25572–25576.
14. Wang YY, Zhao LJ, Wu CF, Lin P, Shi L, et al. (2011) C-KIT mutation co-occurs in patients during bone marrow transplantation. Blood 116: 4452–4455.
15. Kita-bashi Y, Iikawa H, Yokoyama A, Hosoda F, Nagai M, et al. (2001) Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a (8;22)(p11;q15) chromosome translocation. Leukemia 15: 89–94.
16. Fazi F, Zardo G, Gelmetti V, Travaglini L, Cioddi A, et al. (2007) Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood 109: 4432–4450.
17. Giordano A, Avantaggiati ML (1999) p300 and CBP: partners for life and death. J Cell Physiol 181: 218–230.
18. Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 251: 179–186.
19. Bowers EM, Yan G, Makhterje C, Ostry A, Wang L, et al. (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 17: 471–482.
20. Yang M, Kanbe E, Peterson LF, Royapati A, Xiao Y, et al. (2006) A previously unidentified alternatively spliced isoform of (8;21) transcript promotes leukemogenesis. Nat Med 12: 945–949.
21. Fazi F, Zardo G, Gelmetti V, Travaglini L, Cioddi A, et al. (2007) Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood 109: 4432–4450.
22. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, et al. (2010). Refinement of cytogenetic classification in acute myeloid leukemia: determina-
23. Wang YY, Zhao LJ, Wu CF, Lin P, Shi L, et al. (2011) C-KIT mutation co-occurs in patients during bone marrow transplantation. Blood 116: 4452–4455.
24. Kita-bashi Y, Iikawa H, Yokoyama A, Hosoda F, Nagai M, et al. (2001) Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a (8;22)(p11;q15) chromosome translocation. Leukemia 15: 89–94.
25. Kita-bashi Y, Iikawa H, Yokoyama A, Hosoda F, Nagai M, et al. (2001) Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a (8;22)(p11;q15) chromosome translocation. Leukemia 15: 89–94.